Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2022-09-22 20:32:50
Reporting Period:
Accepted Time:
2022-09-22 20:32:50
Original Submission Date:
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1208906 L John Higgins 5980 Horton Street, Suite 405
Emeryville CA 94608
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-09-16 1,000 $88.06 366,180 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
  1. On September 16, 2022, due to an issue with the equity administration system of the company, the reporting person filed a Form 4 which inadvertently reported the sale of a higher number of shares than were actually sold by the reporting person. The correct number of shares sold is listed above.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $88.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.